HER2-Positive Early Breast Cancer: PET-Based, pCR-Adapted Strategy
In the phase II PHERGain trial, researchers found that a positron-emission tomography (PET)-based, pathologic complete response (pCR)-adapted treatment strategy produced “excellent” 3-year invasive di…